On November 12, Veradermics, Inc. fell 12.98% in Regular Trading to $135.7 per share, with turnover of $104.0 million.
The move followed continued market reassessment of the company’s recently reported third-quarter results and follow-up clinical disclosures, despite a narrower-than-expected loss and several recent analyst price-target increases.
Veradermics, Inc. reported a third-quarter net loss of $21.0 million, wider than the $20.1 million loss a year earlier but better than the $26.5 million loss expected by analysts, with no revenue reported. Cash, cash equivalents and marketable securities stood at $798.4 million at September 30, which management said should fund operations into 2030. The company also said VDPHL01 met co-primary efficacy endpoints in two registration-directed male pattern hair loss studies, while initial topline data from the female registration-directed trial remain expected in the first half of 2027. Recent target-price increases included $185 from $150, $175 from $160, and $204 from $170, but those updates did not prevent near-term selling pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments